Generic Name and Formulations:
Haemophilus b conjugate 7.5mcg (meningococcal protein conjugate 250mcg); per 0.5mL; IM inj.
Merck & Co., Inc.
Indications for PEDVAXHIB:
Immunization of children against H. influenzae type b.
<2 months: not recommended. 2 and 4 months: 0.5mL lM. Children vaccinated (with 2 dose regimen) before 12 months should receive booster at 12 months (but not <2 months after previous shot). Previously unvaccinated children, 15–71 months: 0.5mL lM once.
Immunodeficiency. Delay administration in febrile or active infection. Have epinephrine inj (1:1000) available. Protection begins several days after injection. Pregnancy (Cat. C): not recommended.
Local reactions, fever.
Single-dose vials (w. diluent)—10
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness